1. Home
  2. RNXT vs NEPH Comparison

RNXT vs NEPH Comparison

Compare RNXT & NEPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo RenovoRx Inc.

RNXT

RenovoRx Inc.

HOLD

Current Price

$0.89

Market Cap

37.0M

Sector

Health Care

ML Signal

HOLD

Logo Nephros Inc.

NEPH

Nephros Inc.

HOLD

Current Price

$3.56

Market Cap

40.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RNXT
NEPH
Founded
2012
1997
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Medical/Dental Instruments
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
37.0M
40.1M
IPO Year
2021
2004

Fundamental Metrics

Financial Performance
Metric
RNXT
NEPH
Price
$0.89
$3.56
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
2
1
Target Price
$8.25
$6.00
AVG Volume (30 Days)
311.0K
32.0K
Earning Date
05-14-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
20.00
1000.00
EPS
N/A
0.01
Revenue
$1,123,000.00
$18,789,000.00
Revenue This Year
$194.66
$11.24
Revenue Next Year
$279.78
$11.58
P/E Ratio
N/A
$359.00
Revenue Growth
2511.63
32.67
52 Week Low
$0.70
$2.66
52 Week High
$1.45
$6.42

Technical Indicators

Market Signals
Indicator
RNXT
NEPH
Relative Strength Index (RSI) 48.40 47.70
Support Level $0.89 $2.77
Resistance Level $1.07 $3.78
Average True Range (ATR) 0.07 0.20
MACD 0.01 -0.02
Stochastic Oscillator 54.09 8.37

Price Performance

Historical Comparison
RNXT
NEPH

About RNXT RenovoRx Inc.

RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.

About NEPH Nephros Inc.

Nephros Inc is a commercial-stage company that develops and sells high-performance water solutions to the medical and commercial markets. In medical markets, it sells water filtration products and waterborne pathogen detection products. In commercial markets, the company manufactures and sells water filters that improve the taste and odor of water and reduce biofilm, bacteria, and scale build-up in downstream equipment. The company's subsidiary is engaged in the development of its second-generation hemodiafiltration system and other products focused on improving therapies for patients with renal disease. The company generates almost all of revenue from product sales and a small amount from royalty revenue and other revenues.

Share on Social Networks: